Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Bagnasco (Genoa, Italy), M. Caminati (Verona, Italy), F. Menzella (Regio Emilia, Italy), M. Milanese (Pietra Ligure, Italy), A. Bragantini (Genoa, Italy), G. Rolla (Turin, Italy), C. Lombardi (Brescia, Italy), C. Bucca (Turin, Italy), E. Heffler (Milan, Italy), G. Paoletti (Milan, Italy), C. Caruso (Rome, Italy), G. Guida (Turin, Italy), M. Bonavia (Arenzano, Italy), G. Senna (Verona, Italy), G. Canonica (Milan, Italy), G. Passalacqua (Genoa, Italy). One year of mepolizumab in severe asthma in Italy: efficacy and safety. 1650

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial Source: Eur Respir J 2003; 22: 787-794 Year: 2003 Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 A long-term (2 years) efficacy and safety study of doxofylline in the treatment of asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004 Severe asthma outcomes over two years of therapy with mepolizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Three month treatment with formoterol in mild asthma: efficacy and side effects Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Omalizumab in severe uncontrolled asthma: two and a half year clinical experience Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009